By Rishika Sadam Feb 16 (Reuters) - Biocon is aiming for high-double-digit percentage revenue growth as the Indian ...

Biocon will start phase-3 trials for semaglutide in India “soon,” and plans to file for approval by the end of next year, Mittal said. Rivals such as Cipla Ltd. and Torrent Pharmaceuticals Ltd. also ...

Biocon—controlled by Indian pharmaceutical billionaire Kiran Mazumdar-Shaw—is buying the rest of privately held subsidiary Biocon Biologics to consolidate its biosimilars and generics drug businesses.

The biosimilar fracas targeting AbbVie’s megablockbuster Humira is taking shape. But to Biocon Biologics CEO Shreehas Tambe, the battle doesn’t solely revolve around market share. Humira, also known ...

Viatris is letting go of the equity stake it’s held in Biocon’s biosimilar subsidiary Biocon Biologics for $815 million, allowing Biocon to fully integrate its subsidiary. The Viatris stake is one of ...

Thwarted in her ambition to become a brewmaster, Kiran Mazumdar-Shaw channeled her frustrations into building an international knockoff drug powerhouse and has become one of the world’s most ...

Biocon to acquire stakes via share swaps with Serum Institute, Tata Capital, Activ Pine Shreehas Tambe to lead combined entity as CEO, managing director Biocon reviewed IPO, merger options before ...

Indian pharmaceuticals firm Biocon Ltd. will buy out minority shareholders in Biocon Biologics Ltd. via a mix of cash and shares in a deal that values the biosimilars unit at $5.5 billion. Biocon will ...

These new assets are among the largest oncology biologics scheduled to lose exclusivity over the next five years and will join Biocon Biologics’ existing portfolio of 17 oncology medications, which ...